Cerus Corporation (CERS) announced the FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. The approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year.
The company said it is continuing to generate additional data to pursue potential shelf life extension from the FDA beyond 12 months for the INTERCEPT Platelet Processing Sets.
The INTERCEPT Blood System for platelets and plasma is available globally and is the only pathogen reduction system with both CE mark and FDA approval for these two blood components.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.